BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12748663)

  • 1. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
    Mori S; El-Baki H; Mullen CA
    Bone Marrow Transplant; 2003 May; 31(10):865-75. PubMed ID: 12748663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
    Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
    Korngold R; Leighton C; Mobraaten LE; Berger MA
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation.
    Milosevic S; Bachnick B; Karim K; Bornkamm GW; Witter K; Gerbitz A; Mautner J; Behrends U
    Transplantation; 2010 Nov; 90(9):1030-5. PubMed ID: 20802400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.
    Korngold R; Wettstein PJ
    J Immunol; 1990 Dec; 145(12):4079-88. PubMed ID: 2258608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of donor and recipient gender disparities on fatal graft-vs.-host disease in a mouse model for major histocompatibility complex-matched unrelated-donor bone marrow transplantation.
    OKunewick JP; Kociban DL; Machen LL; Buffo MJ
    Exp Hematol; 1993 Nov; 21(12):1570-6. PubMed ID: 8405238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
    Shizuru JA; Jerabek L; Edwards CT; Weissman IL
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):3-14. PubMed ID: 9078349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus.
    Eden PA; Christianson GJ; Fontaine P; Wettstein PJ; Perreault C; Roopenian DC
    J Immunol; 1999 Apr; 162(8):4502-10. PubMed ID: 10201988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
    Friedman TM; Gilbert M; Briggs C; Korngold R
    J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens.
    Berger MA; Korngold R
    J Immunol; 1997 Jul; 159(1):77-85. PubMed ID: 9200441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
    Spaapen R; Mutis T
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.